Key clinical point: PET/CT provided accurate staging information on mantle cell lymphoma without the use of bone marrow biopsy.
Major finding: If greater than 38% of the voxels demonstrated an standard uptake value of less than 0.95, there was a sensitivity of 100% and a specificity of 80%.
Study details: A retrospective cohort study of 23 patients with mantle cell leukemia and 5 controls.
Disclosures: There was no external funding for the study and the researchers reported having no financial disclosures.
Morgan R et al. Clin Lymphoma Myeloma Leuk. 2018 Jul 4. doi: 10.1016/j.clml.2018.06.024.
This Week's Must Reads
Improved myeloma outcomes associated with having prescription drug coverage, Olszewski A et al. J Clin Oncol. 2018 Aug 16. doi: 10.1200/JCO.2018.77.8894
For lymphoma patients, insurance is a matter of life or death , Goldstein JS et al. Blood. 2018 Jul 24. doi: 10.1182/blood-2018-03-839035
Concerns rise over proposal by CMS to level E/M payments , CMS proposed rule, CMS-1693-P
Expansion in clinical trial eligibility requested by ASCO, Friends of Cancer and ASCO letter to the FDA
Promise of broad genomic testing of NSCLC disappoints in community oncology , Presley CJ et al. JAMA. 2018 Aug 7. doi: 10.1001/jama.2018.9824
Must Reads in Lymphoma & Plasma Cell Disorders
Private Insurance Linked to Better Outcomes in Follicular Lymphoma, Goldstein JS et al. Blood. 2018 Jul 24. doi: 10.1182/blood-2018-03-839035.
PET/CT provides MCL staging information, Morgan R et al. Clin Lymphoma Myeloma Leuk. 2018 Jul 4. doi: 10.1016/j.clml.2018.06.024.
Durable responses seen from lisocabtagene in relapsed/refractory DLBCL, Abramson JS et al. ASCO 2018. Abstract 7505
Revised International Pediatric Non-Hodgkin Lymphoma Staging System, Expert panel publishes evidence-based system
Link Between Vitamin D and Lymphoma Survival, Analysis of patients in SWOG and LYSA trials